香港股市 已收市
  • 恒指

    19,258.76
    +258.05 (+1.36%)
     
  • 國指

    6,549.78
    +80.13 (+1.24%)
     
  • 上證綜指

    3,255.65
    +20.74 (+0.64%)
     
  • 道指

    32,244.58
    +382.60 (+1.20%)
     
  • 標普 500

    3,951.57
    +34.93 (+0.89%)
     
  • 納指

    11,675.54
    +45.02 (+0.39%)
     
  • Vix指數

    22.71
    -2.80 (-10.98%)
     
  • 富時100

    7,526.93
    +123.08 (+1.66%)
     
  • 紐約期油

    68.44
    +0.80 (+1.18%)
     
  • 金價

    1,966.80
    -16.00 (-0.81%)
     
  • 美元

    7.8456
    +0.0042 (+0.0536%)
     
  • 人民幣

    0.8753
    -0.0012 (-0.14%)
     
  • 日圓

    0.0591
    -0.0004 (-0.62%)
     
  • 歐元

    8.4543
    +0.0488 (+0.58%)
     
  • Bitcoin

    28,037.10
    -274.58 (-0.97%)
     
  • CMC Crypto 200

    607.43
    +7.76 (+1.29%)
     

Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients

  • Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS).

  • The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.

  • Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients.

  • The treatment regime included Keytruda + Chemo combo, then continued as a single agent every six weeks for up to 14 cycles.

  • At a pre-specified interim analysis review, the regime demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy alone.

  • The safety profile of Keytruda was consistent with that observed in previously reported studies; no new safety signals were identified.

  • This trial was sponsored by the U.S. National Cancer Institute (NCI), part of the National Institutes of Health.

  • Price Action: MRK shares are down 0.63% at $102.81 on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.